Patia is a biotech company that has developed a platform of genetic and technological solutions to prevent the risk of type 2 diabetes and gestational diabetes.
On the International Diabetes Day, which was held yesterday, Talde, through its investee Patia, joins in the promotion of research against this disease, whose evolution is increasingly alarming. The entire scientific community underlines the convenience of preventive measures.
Diabetes currently affects more than 475 million people worldwide. The health, social and economic cost to health systems is great and the expectations for the coming years are worrying.
The firm PATIA, with offices in Mexico City and San Sebastian, and in which the SLIM Foundation, Talde and Corporación Andina de Fomento have a partnership with the Broad Institute of Harvard, MIT (USA) and the Hospital Clínico San Carlos, has developed a platform of genetic tests and technological apps that analyses genetic information and offers personalized measures to prevent the risk and complications of type 2 diabetes and gestational diabetes.. www.patiadiabetes.com.
In summary, its products are already on the market today to prevent the aforementioned risks, which represents a significant advance in the prevention and fight against this type of disease.